Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

[1]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[2]  C. Brennan,et al.  Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence , 2017, Nature Genetics.

[3]  I. Tabbara,et al.  The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia , 2017, Annals of Hematology.

[4]  Frédérick A. Mallette,et al.  Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. , 2017, Trends in cell biology.

[5]  Pedro P. Rocha,et al.  Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. , 2017, Cell reports.

[6]  Simion I. Chiosea,et al.  Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas , 2017, The Journal of pathology.

[7]  Steven J. M. Jones,et al.  Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) , 2017 .

[8]  P. Vertino,et al.  Orphan CpG islands define a novel class of highly active enhancers , 2017, Epigenetics.

[9]  Chris Sander,et al.  Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles , 2017, Cell reports.

[10]  J. Hornick,et al.  Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma , 2017, Modern Pathology.

[11]  Julie M. Batten,et al.  IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. , 2016, Cancer research.

[12]  J. Choi,et al.  Frequent hypermethylation of orphan CpG islands with enhancer activity in cancer , 2016, BMC Medical Genomics.

[13]  A. Iafrate,et al.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer Cell.

[14]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[15]  Darrell,et al.  Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.

[16]  M. Konopleva,et al.  Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.

[17]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[18]  A. Iafrate,et al.  Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Ross,et al.  Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.

[20]  Hai Yan,et al.  Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia* , 2014, The Journal of Biological Chemistry.

[21]  Christian M. Metallo,et al.  IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.

[22]  P. Pandolfi,et al.  Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. , 2014, Cell stem cell.

[23]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[24]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[25]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[26]  W. Kaelin,et al.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.

[27]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[28]  Timothy A. Chan,et al.  Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma , 2012, Oncotarget.

[29]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[30]  Derek Y. Chiang,et al.  Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.

[31]  G. Schackert,et al.  IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas , 2012, Journal of Neuro-Oncology.

[32]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[33]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[34]  A. Futreal,et al.  Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 , 2011, Nature Genetics.

[35]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[36]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[37]  G. Shadel,et al.  Revisiting the TCA cycle: signaling to tumor formation. , 2011, Trends in molecular medicine.

[38]  A. Tefferi,et al.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F , 2011, Leukemia.

[39]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[40]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[41]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[42]  K. Yen,et al.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.

[43]  Xiao Zhang,et al.  Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.

[44]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[45]  Michael Heuser,et al.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.

[46]  D. Birnbaum,et al.  Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.

[47]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[48]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[49]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[50]  M. Snuderl,et al.  Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. , 2018, Methods in molecular biology.

[51]  Richard A. Moore,et al.  Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. , 2017, Cell reports.

[52]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.